Losartan Cost in New York 2026: Cash Price, Medicaid, Insurance, and Compounding

What Is Losartan and Why Does Cost Matter for New York Patients?

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA for hypertension, hypertensive left ventricular hypertrophy (to reduce stroke risk), and diabetic nephropathy in type 2 diabetes patients with elevated creatinine and proteinuria [1]. The drug blocks AT1 receptors, lowering blood pressure without the cough side-effect common to ACE inhibitors. New York has roughly 4.7 million adults with hypertension according to CDC surveillance data [2], making losartan one of the most prescribed drugs in the state.

Because losartan requires daily, lifelong therapy for most patients, even a $20 difference in monthly cost adds up to $240 per year. Understanding your exact cost pathway in New York, whether cash, Medicaid, private insurance, a manufacturer card, or compounding, directly affects adherence. A 2021 analysis in JAMA Internal Medicine found that out-of-pocket cost increases of as little as $10 per month reduced antihypertensive adherence by 8.6% [3]. Poor adherence to antihypertensives is associated with a 33% higher risk of cardiovascular events [4].

Losartan's clinical record is anchored by the LIFE trial (Lancet 2002, N=9,193), which showed losartan reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% versus atenolol (RR 0.87, P<0.001) over 4.8 years, with a 25% relative reduction in fatal and non-fatal stroke [5]. That landmark evidence is why New York Medicaid and most commercial payers consider it a preferred agent.

Generic Losartan Cash Price in New York in 2026

Generic losartan costs approximately $10 per month for a standard 30-day supply at New York retail pharmacies in 2026. That figure applies to the most common doses, 25 mg, 50 mg, and 100 mg tablets, at chains including CVS, Walgreens, Rite Aid, and Walmart Pharmacy locations across the five boroughs and upstate.

Prices vary by dose and by pharmacy. A 90-day supply often costs $20 to $25 cash, making it proportionally cheaper per dose than monthly fills. The FDA's generic drug program, which approved multiple losartan generics between 2010 and 2014, is directly responsible for this price compression [6]. As of 2026, at least 18 FDA-approved generic manufacturers supply losartan to U.S. wholesalers, which keeps retail competition high [6].

Discount programs amplify savings further. GoodRx quotes for losartan 50 mg (30 tablets) at New York City pharmacies typically land between $6 and $12, depending on the specific chain and borough. Mark Cuban's Cost Plus Drugs lists losartan 50 mg at roughly $3.80 for 30 tablets plus a dispensing fee, though delivery timelines vary. The Blink Health platform shows similar figures at participating New York pharmacies.

The brand-name version, Cozaar (Merck), carries a list price near $80 per month. Almost no cash-pay patient benefits from paying that price when therapeutic equivalents are available at one-eighth the cost. The FDA rates all approved generic losartan products as therapeutically equivalent to Cozaar under the "AB" rating [6].

JNC 8 guidelines, published in JAMA in 2014, list ARBs including losartan as a preferred first-line agent for hypertension in adults with chronic kidney disease and in Black adults in combination therapy [7]. That guideline status supports formulary placement and Medicaid coverage that keeps patient costs low.

New York Medicaid Coverage for Losartan

New York Medicaid covers losartan for hypertension, heart failure, and diabetic nephropathy, but prior authorization (PA) is required in most managed care plans operating under the New York Medicaid Managed Care program. The PA requirement typically asks prescribers to document the indication, confirm the patient has tried or is contraindicated to ACE inhibitors, and submit a brief clinical note [8].

New York's Medicaid fee-for-service formulary places generic losartan on a preferred tier. Copays for Medicaid enrollees in New York range from $0 to $3 per prescription depending on the managed care organization (MCO) and the patient's Medicaid category (full benefit versus partial benefit). Patients enrolled in the Essential Plan, New York's state-funded coverage program for individuals between 138% and 200% of the federal poverty level, generally pay $0 for preferred generics including losartan [8].

New York's HIV Special Needs Plans and Health and Recovery Plans (HARPs) also cover losartan on standard formularies, reflecting the drug's broad cardiovascular indication profile. Patients with dual Medicaid and Medicare enrollment (dual eligibles) typically access losartan through their Medicare Part D plan at the $0 to $4 copay tier under the Low Income Subsidy (LIS/Extra Help) program [9].

The 2024 American College of Cardiology/American Heart Association hypertension guideline recommends ARBs as first-line therapy for hypertension in patients with heart failure with reduced ejection fraction, CKD, or diabetes [10]. New York Medicaid's PA criteria align with this recommendation, meaning most patients who meet clinical criteria should clear prior authorization without difficulty.

Commercial Insurance Coverage of Losartan in New York

Most commercial insurance plans sold on the New York State of Health (NYSOH) marketplace and through large employers place generic losartan on Tier 1 or Tier 2, producing monthly copays between $0 and $15 for most enrollees. Major payers operating in New York, including Emblem Health, Healthfirst, MetroPlus, Empire BlueCross BlueShield, Oscar Health, and United Healthcare Oxford, all include generic losartan on preferred formulary tiers as of 2026.

Patients on high-deductible health plans (HDHPs) pay full retail cost until their deductible is met, which is where GoodRx or Cost Plus Drugs discounts often undercut the insurance pricing. A patient with a $1,500 deductible filling losartan in January would pay $10 cash with a GoodRx coupon rather than $20 to $30 against their deductible at a standard retail rate.

Specialty and brand-name Cozaar coverage is more variable. Several New York exchange plans exclude brand Cozaar entirely when a generic is available, a practice permitted under the ACA's non-interference provisions. Patients who specifically require brand-name Cozaar for documented clinical reasons (such as tablet size constraints for dose titration in pediatric patients) may need a PA and a step-therapy override [11].

The Consolidated Appropriations Act of 2021 placed new restrictions on step-therapy programs for commercial plans regulated by New York State, requiring payers to respond to override requests within 72 hours in non-urgent cases and within one business day in urgent cases [12]. This matters for losartan patients who face formulary barriers to the specific formulation their prescriber has chosen.

Merck Cozaar Savings Card and Manufacturer Programs

Merck offers a savings card for Cozaar (brand losartan) through its patient assistance infrastructure, but eligibility rules and program terms change frequently. In 2026, the Merck Patient Assistance Program (Merck Helps) provides Cozaar at no cost to uninsured patients with income at or below 600% of the federal poverty level [13]. The application requires proof of income and a valid prescription.

For commercially insured patients, the Merck savings card historically capped out-of-pocket costs at $5 per month on brand Cozaar, but this program excludes patients on government insurance including Medicaid, Medicare, and CHIP. New York patients on those programs cannot legally use manufacturer copay assistance cards for brand Cozaar under federal anti-kickback rules [14].

Given that generic losartan costs $10 or less per month cash, the manufacturer savings card primarily benefits patients whose prescriber insists on brand Cozaar and who have commercial insurance placing it on a high-cost tier. For most New York patients, pursuing generic losartan through a discount platform provides equivalent savings with far less administrative friction.

Compounded Losartan in New York: Legality and Cost

Compounded losartan is legal in New York when prepared by a state-licensed 503A pharmacy operating under New York State Board of Pharmacy oversight and in compliance with USP Chapter 795 standards for non-sterile preparations [15]. The 503A designation means the pharmacy compounds for individual patients based on a valid prescriber order rather than manufacturing in bulk for resale, which would require 503B outsourcing facility registration [15].

New York's compounding framework is among the more strictly supervised in the United States. The New York State Board of Pharmacy conducts routine inspections of 503A pharmacies and enforces compliance with the state's compounding regulations under Public Health Law Section 6802-a [16]. Prescribers and patients should confirm that any compounding pharmacy they use holds an active New York State pharmacy license, searchable through the Office of the Professions online verification portal.

Why would a patient seek compounded losartan when generic tablets cost $10 per month? Three scenarios apply. First, patients who require a dose not commercially available (such as 12.5 mg for elderly patients with renal impairment) may need a compounded preparation. Second, patients with tablet-component allergies (such as to lactose or specific dyes in commercial tablets) may need alternative formulations. Third, some HealthRX patients access losartan as part of a compound cardiometabolic formulation that combines it with other agents in a single oral preparation, subject to prescriber judgment and compounding pharmacy capabilities.

The cost of compounded losartan through a 503A pharmacy in New York can approach $0 per month for patients whose telehealth plan covers it within a bundled subscription, compared to $10 for generic retail. That difference is modest in isolation, but patients managing multiple compounded medications may see meaningful total savings.

FDA guidance from 2023 clarified that compounded losartan does not appear on the FDA's Difficult to Compound list, and losartan potassium is commercially available as a bulk drug substance, meaning 503A pharmacies may use it legally [17]. Prescribers should document medical necessity in the chart when ordering compounded versus commercial losartan to satisfy both pharmacy board and payer documentation standards.

Telehealth Prescribing of Losartan in New York

Losartan can be prescribed via telehealth in New York. The drug is not a controlled substance, so it does not face the same prescribing restrictions that apply to Schedule II through IV medications under the Ryan Haight Act or its post-pandemic successors [18]. A New York-licensed prescriber conducting a synchronous audio-video visit may diagnose hypertension, review a patient's blood pressure log and recent labs, and issue a losartan prescription without an in-person examination, provided the clinical encounter meets the standard of care [18].

New York's telehealth parity law, enacted under Public Health Law Section 2999-cc, requires commercial insurers and Medicaid MCOs to reimburse telehealth visits at the same rate as in-person visits for services within the scope of the law [19]. This means a patient obtaining a losartan prescription via a HealthRX telehealth visit faces the same copay as an in-person office visit for that service.

Monitoring requirements do matter. Losartan therapy requires baseline serum creatinine, potassium, and blood pressure measurement before initiation, and follow-up labs at 2 to 4 weeks after starting or after dose changes per standard nephrology and cardiology practice [10]. Telehealth platforms that integrate with at-home blood pressure cuffs and order labs through national reference laboratories (LabCorp, Quest) can fulfill these monitoring requirements without requiring an in-person visit for stable patients.

The New York State Department of Health published updated telehealth prescribing guidance in 2023 confirming that prescribers must establish a valid patient-provider relationship prior to prescribing, which an initial video visit satisfies for non-controlled medications [19]. Patients should confirm their telehealth provider is licensed in New York and that the visit is documented in a medical record.

Losartan Dosing, Safety, and Monitoring Costs

Losartan is dosed once daily. The starting dose for hypertension is typically 50 mg, with titration to 100 mg if the blood pressure response is inadequate at 4 to 6 weeks [1]. For diabetic nephropathy, the RENAAL trial (N=1,513) showed that losartan 50 mg to 100 mg daily reduced the composite of doubling of serum creatinine, ESRD, or death by 16% versus placebo (P=0.02) over a mean of 3.4 years [20]. For stroke risk reduction in hypertensive patients with left ventricular hypertrophy, the LIFE trial demonstrated benefit starting at 50 mg with up-titration to 100 mg plus hydrochlorothiazide as needed [5].

Monitoring adds to total treatment cost. A basic metabolic panel (BMP) checking creatinine and potassium typically costs $15 to $40 at a reference lab with a GoodRx-style discount, or $0 to $10 under most insurance plans. The FDA label for losartan instructs prescribers to monitor renal function and serum electrolytes periodically, with increased frequency in patients with renal impairment or those also taking potassium-sparing diuretics [1].

Hyperkalemia risk is the primary electrolyte concern. In the ONTARGET trial (N=25,620), dual blockade with an ARB plus an ACE inhibitor increased hyperkalemia events significantly compared with monotherapy (RR 2.28, P<0.001), which is why combination use is generally avoided [21]. New York prescribers ordering losartan via telehealth should review concurrent potassium supplementation and NSAID use, both of which raise serum potassium.

Pregnancy is an absolute contraindication. Losartan carries a Black Box Warning for fetal toxicity; the FDA label states the drug should be discontinued as soon as pregnancy is detected [1]. New York providers must counsel patients of reproductive potential about this risk at every prescribing encounter, including telehealth visits.

Lowest-Cost Pathways for New York Patients: A Practical Comparison

Getting losartan for the lowest possible cost in New York in 2026 depends on insurance status and individual clinical factors. The table below summarizes the realistic monthly cost for each access pathway.

Uninsured or underinsured, cash pay: Use GoodRx or Cost Plus Drugs at a participating New York pharmacy. Realistic cost: $4 to $10 per month for generic losartan 50 mg.

New York Medicaid (full benefit): Obtain prior authorization from your prescriber. After PA approval, copay is $0 to $3 per month.

Essential Plan (138-200% FPL): Preferred generic losartan is typically $0 per month.

Commercial insurance (Tier 1/2 formulary): Copay is $0 to $15 per month. Use GoodRx as a fallback if it undercuts your insurance copay, which it sometimes does for patients with high deductibles.

Medicare Part D with Low Income Subsidy: $0 to $4 per month at a pharmacy contracted with your Part D plan.

Compounded losartan via HealthRX or similar telehealth platform: Cost varies by plan structure; some subscription-based platforms include compounded medications for a flat monthly fee that may be lower than pharmacy retail for patients already paying for the telehealth subscription.

Merck Patient Assistance (Cozaar brand, uninsured): $0 per month for patients at or below 600% FPL who complete the Merck Helps application [13]. Processing takes 2 to 4 weeks; a 30-day bridge supply may be needed.

The New York State Pharmaceutical Assistance Contract for the Elderly (PACE) program provides drug cost assistance to New Yorkers aged 65 and older who exceed Medicare Part D income thresholds. PACE covers a broad formulary including antihypertensives, and eligible patients should apply through the New York State Office for the Aging [22].

New York-Specific Discount and Assistance Programs

Several programs layer additional savings on top of the options above for New York residents specifically.

The New York Rx Card is a free state-endorsed prescription discount card available to all New York residents regardless of income or insurance status, administered through the New York State Office for the Aging and available at county offices across the state [22]. It negotiates rates at participating pharmacies and can reduce losartan costs by 15% to 45% compared with retail.

NeedyMeds.org maintains a real-time database of patient assistance programs accessible to New York residents, including disease-specific funds and pharmacy discount networks. The database is searchable by drug name and zip code [23].

The Community Health Center network in New York, including Federally Qualified Health Centers (FQHCs) operating under Section 330 of the Public Health Service Act, provides access to the 340B drug pricing program. Under 340B, qualifying patients can obtain losartan at deeply discounted prices, often below $5 per month, at FQHC-affiliated pharmacies [24]. New York has more than 80 FQHC sites across the state.

RxAssist.org catalogs manufacturer patient assistance programs and foundation grants accessible to New York patients, including those from the PAN Foundation and the HealthWell Foundation, both of which fund cardiovascular medication copays for eligible patients [25].